Literature DB >> 18772671

Advances in evaluation and management of pediatric idiopathic intracranial hypertension.

Alvit Wolf1, Kelly A Hutcheson.   

Abstract

PURPOSE OF REVIEW: Although the demographics of pediatric idiopathic intracranial hypertension have been well described, the best approaches to its management are less well defined. Recent advances in evaluation of optic nerve status make it easier to determine when and if more aggressive intervention is required. Medical and surgical approaches are discussed. RECENT
FINDINGS: Modern neuroimaging techniques are used to look for secondary causes of intracranial hypertension such as cerebral venous sinus thrombosis. Automated perimetry is now quicker to perform and is accepted as the gold standard in evaluating optic nerve defects, even in the pediatric population. Other newer techniques for assessing optic nerve injury include optical coherence tomography, laser scanning tomography, and spectral Doppler blood flow analysis of the optic nerve head. Medical management remains the first-line treatment, but increasingly, surgical interventions such as optic nerve sheath fenestration and cerebrospinal fluid shunting are used in the pediatric population.
SUMMARY: Pediatric intracranial hypertension patients may be followed with a greater degree of precision than in the past. Management tends to be similar to that used in adults, now including surgical intervention when indicated. The newer technologies allow us to gather data that may help to determine the optimal time for surgical intervention for those patients who require it.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772671     DOI: 10.1097/ICU.0b013e328309f1b6

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  9 in total

1.  [Progressive blindness of a young female with extreme obesity].

Authors:  Th Bertelmann; W Sekundo
Journal:  Internist (Berl)       Date:  2010-09       Impact factor: 0.743

2.  Idiopathic intracranial hypertension in children: Diagnostic and management approach.

Authors:  Abdulrahman Albakr; Muddathir H Hamad; Ali H Alwadei; Fahad A Bashiri; Hamdy H Hassan; Hiyam Idris; Saeed Hassan; Taim Muayqil; Ikhlass Altweijri; Mustafa A Salih
Journal:  Sudan J Paediatr       Date:  2016

3.  A case of pediatric idiopathic intracranial hypertension presenting with divergence insufficiency.

Authors:  Hae Min Kang; Hye Young Kim
Journal:  Korean J Ophthalmol       Date:  2011-07-22

4.  Management of pediatric patients with pseudotumor cerebri.

Authors:  Joshua J Chern; R Shane Tubbs; Amber S Gordon; Katherine J Donnithorne; W Jerry Oakes
Journal:  Childs Nerv Syst       Date:  2012-01-19       Impact factor: 1.475

5.  Guiding follow-up of paediatric idiopathic intracranial hypertension with optical coherence tomography.

Authors:  Kai Guo Benny Loo; Su Ann Lim; I-Linn Zena Lim; Derrick Wei Shih Chan
Journal:  BMJ Case Rep       Date:  2016-03-03

Review 6.  Diagnosis and treatment of idiopathic intracranial hypertension (IIH) in children and adolescents.

Authors:  M Cristina Victorio; A David Rothner
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

Review 7.  Intracranial hypotension and hypertension in children and adolescents.

Authors:  Aynur Ozge; Hayrunnisa Bolay
Journal:  Curr Pain Headache Rep       Date:  2014-07

8.  Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT.

Authors:  Falko Kaufhold; Ella Maria Kadas; Christoph Schmidt; Hagen Kunte; Jan Hoffmann; Hanna Zimmermann; Timm Oberwahrenbrock; Lutz Harms; Konrad Polthier; Alexander U Brandt; Friedemann Paul
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

9.  Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment.

Authors:  Ülkü Gül; Ayşe Kaçar Bayram; Mustafa Kendirci; Nihal Hatipoğlu; Deniz Okdemir; Hakan Gümüş; Selim Kurtoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-04-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.